Propionic acid derivative and use thereof in medicine

A compound or a stereoisomer, mesomer/racemate, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, which compound is selected from a compound of general formula (I), wherein

• R1 is selected from —CHR1aR1b or —NR1aR1b;
• R1a is selected from C1-6 alkyl, wherein the alkyl is optionally substituted with 0 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl, C1-6 alkoxy or C3-6 cycloalkyl;
• R1b is selected from C4-10 carbocyclic ring or 5- to 10-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted with 0 to 4 Rb, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S or N;
• each Rb is independently selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, —C0-4 alkyl-NHC1-6 alkyl, —C0-4 alkyl-N(C1-6 alkyl)2, C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, —C0-4 alkyl-C3-10 carbocyclic ring, —C0-4 alkyl-3- to 10-membered heterocyclic ring or Rba, wherein the alkyl, alkynyl, alkoxy, carbocyclic ring or heterocyclic ring is optionally substituted with 0 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, CONH2, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, N(C1-6 alkyl)(C3-6 cycloalkyl), NH(C3-6 cycloalkyl), C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, halogen-substituted C1-6 alkyl, halogen-substituted C1-6 alkoxy, C1-6 alkoxyalkyl or Rk, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S or N;
• Rba is selected from —C0-4 alkyl-7- to 12-membered heterocyclic ring, —C0-4 alkyl-4- to 6-membered heterocyclic ring connected via a carbon atom,
• and the Rba is optionally substituted with 1 to 4 substituents selected from H, halogen, OH, ═O, cyano, COOH, CONH2, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, halogen-substituted C1-6 alkyl, halogen-substituted C1-6 alkoxy, C1-6 alkoxyalkyl or Rk, wherein the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S or N;
• Rk is selected from —C1-4 alkyl-NH2, —C1-4 alkyl-NHC1-6 alkyl, —C1-4 alkyl-N(C1-6 alkyl)2, —C0-4 alkyl-C3-10 carbocyclic ring or —C0-4 alkyl-3- to 10-membered heterocyclic ring, wherein the alkyl, carbocyclic ring or heterocyclic ring is optionally substituted with 1 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl, C1-6 alkoxy, halogen-substituted C1-6 alkyl, halogen-substituted C1-6 alkoxy or C1-6 alkoxyalkyl, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S or N;
• R2 is selected from C1-6 alkyl, C6-10 aromatic ring, 5- to 10-membered heteroaromatic ring, C3-10 carbocyclic ring or 5- to 10-membered heterocyclic ring, and the R2 is optionally substituted with 0 to 4 R2a, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 4 heteroatoms selected from O, S or N;
• each R2a is independently selected from deuterium, halogen, OH, cyano, ═O, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, or heterocyclyl is optionally substituted with 0 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl or C1-6 alkoxy, and the heterocyclyl contains 1 to 3 heteroatoms selected from N, O or S;
• as an option, R2a and R2a are directly linked to form C4-7 carbocyclic ring or 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted with 1 to 4 substituents selected from deuterium, halogen, OH, cyano, ═O, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl or 3- to 7-membered heterocycloalkyl, and the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl or heterocycloalkyl is optionally substituted with 1 to 4 substituents selected from deuterium, halogen, OH or cyano;
• R3 is selected from H or C1-6 alkyl, wherein the alkyl is optionally substituted with 0 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl, C1-6 alkoxy or C3-6 carbocyclic ring;
• ring A is selected from C8-10 fused carbocyclic ring, and the ring A is optionally substituted with 0 to 4 Ra5;
• or ring A is selected from
• and the ring A is substituted with one substituent selected from C2-6 alkenyl or C2-6 alkynyl and optionally substituted with 1 to 3 Ra5;
• Ra5 is selected from halogen, OH, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, or 3- to 7-membered heterocyclyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, or heterocyclyl is optionally substituted with 0 to 4 substituents selected from deuterium, halogen, OH, ═O, cyano, COOH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-6 alkyl, C1-6 alkoxy or C3-6 cycloalkyl, and the heterocyclyl contains 1 to 3 heteroatoms selected from N, O or S.